Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)
Taiwan · Delayed Price · Currency is TWD 30.95
+0.05 (0.16%)
Jan 22, 2026, 1:35 PM CST
Sinphar Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 3,346 | 3,151 | 2,963 | 2,857 | 2,434 | 2,388 | Upgrade | |
Revenue Growth (YoY) | 9.88% | 6.33% | 3.72% | 17.39% | 1.89% | -0.26% | Upgrade |
Cost of Revenue | 1,920 | 1,910 | 1,869 | 1,764 | 1,545 | 1,513 | Upgrade |
Gross Profit | 1,425 | 1,240 | 1,094 | 1,093 | 888.71 | 875.53 | Upgrade |
Selling, General & Admin | 867.53 | 791.65 | 670.93 | 621.34 | 557.06 | 537.16 | Upgrade |
Research & Development | 146.88 | 151.36 | 132.58 | 272.16 | 511.88 | 462.4 | Upgrade |
Operating Expenses | 1,014 | 943.15 | 805.19 | 893.97 | 1,071 | 997.73 | Upgrade |
Operating Income | 411 | 297.16 | 288.74 | 198.63 | -182.77 | -122.2 | Upgrade |
Interest Expense | -35.58 | -36.77 | -33.71 | -27.81 | -24.8 | -24.51 | Upgrade |
Interest & Investment Income | 15.71 | 16.84 | 12.31 | 5.78 | 3.68 | 3.8 | Upgrade |
Currency Exchange Gain (Loss) | -9.62 | 13.43 | 3.79 | 21.31 | -6.96 | -12.61 | Upgrade |
Other Non Operating Income (Expenses) | 18.71 | 18.93 | 29.46 | 47.96 | 27.82 | 37.6 | Upgrade |
EBT Excluding Unusual Items | 400.22 | 309.58 | 300.58 | 245.86 | -183.03 | -117.92 | Upgrade |
Gain (Loss) on Sale of Investments | 0.08 | - | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -1.08 | -2.48 | 5.13 | -0.81 | -1.5 | 0.14 | Upgrade |
Pretax Income | 399.22 | 307.1 | 305.71 | 245.05 | -184.53 | -117.77 | Upgrade |
Income Tax Expense | 64.75 | 21.88 | -51.07 | 80.87 | 20.43 | 54.79 | Upgrade |
Earnings From Continuing Operations | 334.47 | 285.22 | 356.78 | 164.17 | -204.96 | -172.56 | Upgrade |
Minority Interest in Earnings | 11.1 | 19.49 | 18.39 | 60.47 | 166.82 | 144.05 | Upgrade |
Net Income | 345.57 | 304.71 | 375.17 | 224.64 | -38.14 | -28.51 | Upgrade |
Net Income to Common | 345.57 | 304.71 | 375.17 | 224.64 | -38.14 | -28.51 | Upgrade |
Net Income Growth | 3.84% | -18.78% | 67.01% | - | - | - | Upgrade |
Shares Outstanding (Basic) | 190 | 190 | 190 | 190 | 190 | 190 | Upgrade |
Shares Outstanding (Diluted) | 191 | 191 | 191 | 191 | 190 | 190 | Upgrade |
Shares Change (YoY) | 0.07% | 0.02% | -0.00% | 0.17% | - | -0.07% | Upgrade |
EPS (Basic) | 1.82 | 1.60 | 1.97 | 1.18 | -0.20 | -0.15 | Upgrade |
EPS (Diluted) | 1.81 | 1.60 | 1.97 | 1.18 | -0.20 | -0.15 | Upgrade |
EPS Growth | 3.44% | -18.84% | 66.91% | - | - | - | Upgrade |
Free Cash Flow | 399.82 | 353.08 | 0.86 | 283.82 | -10.64 | 2.38 | Upgrade |
Free Cash Flow Per Share | 2.10 | 1.85 | 0.01 | 1.49 | -0.06 | 0.01 | Upgrade |
Dividend Per Share | 0.952 | 0.952 | 0.882 | 0.882 | 0.176 | 0.176 | Upgrade |
Dividend Growth | 7.99% | 7.99% | 0.01% | 399.89% | - | - | Upgrade |
Gross Margin | 42.60% | 39.37% | 36.92% | 38.25% | 36.52% | 36.66% | Upgrade |
Operating Margin | 12.28% | 9.43% | 9.74% | 6.95% | -7.51% | -5.12% | Upgrade |
Profit Margin | 10.33% | 9.67% | 12.66% | 7.86% | -1.57% | -1.19% | Upgrade |
Free Cash Flow Margin | 11.95% | 11.21% | 0.03% | 9.93% | -0.44% | 0.10% | Upgrade |
EBITDA | 652.98 | 539.99 | 518.14 | 446.69 | 63.93 | 112.68 | Upgrade |
EBITDA Margin | 19.52% | 17.14% | 17.49% | 15.64% | 2.63% | 4.72% | Upgrade |
D&A For EBITDA | 241.98 | 242.83 | 229.4 | 248.06 | 246.7 | 234.88 | Upgrade |
EBIT | 411 | 297.16 | 288.74 | 198.63 | -182.77 | -122.2 | Upgrade |
EBIT Margin | 12.28% | 9.43% | 9.74% | 6.95% | -7.51% | -5.12% | Upgrade |
Effective Tax Rate | 16.22% | 7.13% | - | 33.00% | - | - | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.